Intarcia’s Fight To Win ITCA 650 Approval: Former Employees Object To FDA AdComm Presentations

 
• By Brenda Sandburg

In another case of criticism after an adcomm, three former Intarcia employees, including the key developer of the ITCA 650 device, contend agency made ‘erroneous statements’ about performance and manufacturing to the advisory committee that voted unanimously against the type 2 diabetes treatment.

Conflict
Former Intarcia employees back company in dispute with FDA over diabetes drug-device combo product. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers